191 related articles for article (PubMed ID: 37945755)
41. Carfilzomib 56 mg/m
Weisel K; Nooka AK; Terpos E; Spencer A; Goldschmidt H; Dirnberger F; DeCosta L; Yusuf A; Kumar S
Leuk Lymphoma; 2022 Aug; 63(8):1887-1896. PubMed ID: 35289710
[TBL] [Abstract][Full Text] [Related]
42. Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial.
Jackson GH; Pawlyn C; Cairns DA; de Tute RM; Hockaday A; Collett C; Jones JR; Kishore B; Garg M; Williams CD; Karunanithi K; Lindsay J; Rocci A; Snowden JA; Jenner MW; Cook G; Russell NH; Drayson MT; Gregory WM; Kaiser MF; Owen RG; Davies FE; Morgan GJ;
PLoS Med; 2021 Jan; 18(1):e1003454. PubMed ID: 33428632
[TBL] [Abstract][Full Text] [Related]
43. Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond.
Chim CS; Kumar SK; Orlowski RZ; Cook G; Richardson PG; Gertz MA; Giralt S; Mateos MV; Leleu X; Anderson KC
Leukemia; 2018 Feb; 32(2):252-262. PubMed ID: 29257139
[TBL] [Abstract][Full Text] [Related]
44. Renal recovery following daratumumab, lenalidomide, and dexamethasone therapy in a patient with newly diagnosed dialysis-dependent multiple myeloma.
Mizuno S; Kitayama C; Mashiko S; Sanada S
CEN Case Rep; 2022 May; 11(2):265-268. PubMed ID: 34817845
[TBL] [Abstract][Full Text] [Related]
45. Sequencing multiple myeloma therapies with and after antibody therapies.
van de Donk NWCJ
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):248-258. PubMed ID: 33275724
[TBL] [Abstract][Full Text] [Related]
46. Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Plesner T; Arkenau HT; Gimsing P; Krejcik J; Lemech C; Minnema MC; Lassen U; Laubach JP; Palumbo A; Lisby S; Basse L; Wang J; Sasser AK; Guckert ME; de Boer C; Khokhar NZ; Yeh H; Clemens PL; Ahmadi T; Lokhorst HM; Richardson PG
Blood; 2016 Oct; 128(14):1821-1828. PubMed ID: 27531679
[TBL] [Abstract][Full Text] [Related]
47. Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome Group.
Samur MK; Aktas Samur A; Fulciniti M; Szalat R; Han T; Shammas M; Richardson P; Magrangeas F; Minvielle S; Corre J; Moreau P; Thakurta A; Anderson KC; Parmigiani G; Avet-Loiseau H; Munshi NC
J Clin Oncol; 2020 Sep; 38(27):3107-3118. PubMed ID: 32687451
[TBL] [Abstract][Full Text] [Related]
48. Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial.
Manasanch EE; Shah JJ; Lee HC; Weber DM; Thomas SK; Amini B; Feng L; Berkova Z; Hildebrandt M; Orlowski RZ
Lancet Haematol; 2018 Dec; 5(12):e628-e640. PubMed ID: 30501870
[TBL] [Abstract][Full Text] [Related]
49. Should all newly diagnosed MM patients receive CD38 antibody-based treatment?
Korst CLBM; van de Donk NWCJ
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):259-263. PubMed ID: 33275735
[TBL] [Abstract][Full Text] [Related]
50. Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.
Facon T; Kumar S; Plesner T; Orlowski RZ; Moreau P; Bahlis N; Basu S; Nahi H; Hulin C; Quach H; Goldschmidt H; O'Dwyer M; Perrot A; Venner CP; Weisel K; Mace JR; Raje N; Attal M; Tiab M; Macro M; Frenzel L; Leleu X; Ahmadi T; Chiu C; Wang J; Van Rampelbergh R; Uhlar CM; Kobos R; Qi M; Usmani SZ;
N Engl J Med; 2019 May; 380(22):2104-2115. PubMed ID: 31141632
[TBL] [Abstract][Full Text] [Related]
51. Monoclonal Antibodies in Multiple Myeloma: A New Wave of the Future.
Sherbenou DW; Mark TM; Forsberg P
Clin Lymphoma Myeloma Leuk; 2017 Sep; 17(9):545-554. PubMed ID: 28734795
[TBL] [Abstract][Full Text] [Related]
52. Daratumumab in first-line therapy is cost-effective in transplant-eligible patients with newly diagnosed myeloma.
Yamamoto C; Minakata D; Koyama S; Sekiguchi K; Fukui Y; Murahashi R; Nakashima H; Matsuoka S; Ikeda T; Kawaguchi SI; Toda Y; Ito S; Nagayama T; Umino K; Nakano H; Morita K; Yamasaki R; Ashizawa M; Ueda M; Hatano K; Sato K; Ohmine K; Fujiwara SI; Kanda Y
Blood; 2022 Aug; 140(6):594-607. PubMed ID: 35580269
[TBL] [Abstract][Full Text] [Related]
53. Immunomodulators in newly diagnosed multiple myeloma: current and future concepts.
Delforge M; Vlayen S; Kint N
Expert Rev Hematol; 2021 Apr; 14(4):365-376. PubMed ID: 33733978
[No Abstract] [Full Text] [Related]
54. Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab.
Casneuf T; Adams HC; van de Donk NWCJ; Abraham Y; Bald J; Vanhoof G; Van der Borght K; Smets T; Foulk B; Nielsen KC; Rusbuldt J; Axel A; Lysaght A; Ceulemans H; Stevenaert F; Usmani SZ; Plesner T; Avet-Loiseau H; Nijhof I; Mutis T; Schecter JM; Chiu C; Bahlis NJ
Leukemia; 2021 Feb; 35(2):573-584. PubMed ID: 32457357
[TBL] [Abstract][Full Text] [Related]
55. Immunotherapy: A New Approach to Treating Multiple Myeloma with Daratumumab and Elotuzumab.
Afifi S; Michael A; Lesokhin A
Ann Pharmacother; 2016 Jul; 50(7):555-68. PubMed ID: 27083916
[TBL] [Abstract][Full Text] [Related]
56. MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial.
Raab MS; Engelhardt M; Blank A; Goldschmidt H; Agis H; Blau IW; Einsele H; Ferstl B; Schub N; Röllig C; Weisel K; Winderlich M; Griese J; Härtle S; Weirather J; Jarutat T; Peschel C; Chatterjee M
Lancet Haematol; 2020 May; 7(5):e381-e394. PubMed ID: 32171061
[TBL] [Abstract][Full Text] [Related]
57. Immunomodulatory effects of CD38-targeting antibodies.
van de Donk NWCJ
Immunol Lett; 2018 Jul; 199():16-22. PubMed ID: 29702148
[TBL] [Abstract][Full Text] [Related]
58. New developments in the treatment of multiple myeloma - clinical utility of daratumumab.
McEllistrim C; Krawczyk J; O'Dwyer ME
Biologics; 2017; 11():31-43. PubMed ID: 28442888
[TBL] [Abstract][Full Text] [Related]
59. Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide.
Nijhof IS; Lammerts van Bueren JJ; van Kessel B; Andre P; Morel Y; Lokhorst HM; van de Donk NW; Parren PW; Mutis T
Haematologica; 2015 Feb; 100(2):263-8. PubMed ID: 25510242
[TBL] [Abstract][Full Text] [Related]
60. Multiple Myeloma: Clinical Updates From the American Society of Hematology Annual Meeting 2018.
Terpos E; Ntanasis-Stathopoulos I;
Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):e324-e336. PubMed ID: 31076371
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
